Hypertension, Vol 8, 1089-1092, Copyright © 1986 by American Heart Association
A Benetos, I Gavras and H Gavras
The purpose of these experiments was to study the possible contribution of
bradykinin to normal blood pressure maintenance. The bradykinin analogue
B4146, a competitive antagonist-partial agonist of bradykinin, was used in
three groups of normotensive unanesthetized Wistar rats. Two intra-aortic
injections of B4146 (1 mg in 0.2 ml of dextrose) were given 5 minutes apart
(i.e., well after return of blood pressure to baseline, which occurred
within 68 +/- 19 seconds). One group had been pretreated with the
angiotensin converting enzyme inhibitor HOE 498, 1 mg/kg (Hoechst), and one
received only dextrose as the first injection to serve as controls. The
bradykinin antagonist produced an average increase in mean arterial
pressure of approximately 13 mm Hg for all groups. In five animals,
however, the first injection of B4146 produced a hypotensive effect,
whereas the second one consistently produced a rise in blood pressure.
Pretreatment with the angiotensin converting enzyme inhibitor did not
affect the magnitude of the subsequent blood pressure increase in response
to B4146. Since smaller doses of B4146, sufficient to block exogenous
bradykinin, do not cause changes in normal blood pressure, we conclude that
endogenous bradykinin does contribute to normal blood pressure maintenance,
but its effect can be demonstrated only if very high doses of its
antagonist are injected, maybe because a high concentration of the compound
is necessary to displace not only circulating but possibly tissue
receptor-bound bradykinin as well.
ARTICLES
Hypertensive effect of a bradykinin antagonist in normotensive rats
This article has been cited by other articles:
![]() |
A. Duka, E. Kintsurashvili, I. Duka, D. Ona, T. A. Hopkins, M. Bader, I. Gavras, and H. Gavras Angiotensin-Converting Enzyme Inhibition After Experimental Myocardial Infarct: Role of the Kinin B1 and B2 Receptors Hypertension, May 1, 2008; 51(5): 1352 - 1357. [Abstract] [Full Text] [PDF] |
||||
![]() |
A. Duka, I. Duka, G. Gao, S. Shenouda, I. Gavras, and H. Gavras Role of bradykinin B1 and B2 receptors in normal blood pressure regulation Am J Physiol Endocrinol Metab, August 1, 2006; 291(2): E268 - E274. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Duka, A. Duka, E. Kintsurashvili, C. Johns, I. Gavras, and H. Gavras Mechanisms Mediating the Vasoactive Effects of the B1 Receptors of Bradykinin Hypertension, November 1, 2003; 42(5): 1021 - 1025. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Kintsurashvili, I. Duka, I. Gavras, C. Johns, D. Farmakiotis, and H. Gavras Effects of ANG II on bradykinin receptor gene expression in cardiomyocytes and vascular smooth muscle cells Am J Physiol Heart Circ Physiol, October 1, 2001; 281(4): H1778 - H1783. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Duka, E. Kintsurashvili, I. Gavras, C. Johns, M. Bresnahan, and H. Gavras Vasoactive Potential of the B1 Bradykinin Receptor in Normotension and Hypertension Circ. Res., February 16, 2001; 88(3): 275 - 281. [Abstract] [Full Text] [PDF] |
||||
![]() |
N.-E. Rhaleb, X.-P. Yang, M. Nanba, E. G. Shesely, and O. A. Carretero Effect of Chronic Blockade of the Kallikrein-Kinin System on the Development of Hypertension in Rats Hypertension, January 1, 2001; 37(1): 121 - 128. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Pasquie, A. Herizi, B. Jover, and A. Mimran Chronic Bradykinin Infusion and Receptor Blockade in Angiotensin II Hypertension in Rats Hypertension, March 1, 1999; 33(3): 830 - 834. [Abstract] [Full Text] [PDF] |
||||
![]() |
W. R. Fitzgibbon, A. A. Jaffa, R. K. Mayfield, and D. W. Ploth Role of Kinins in the Renal Response to Enalaprilat in Normotensive and Hypertensive Rats Hypertension, February 1, 1996; 27(2): 235 - 244. [Abstract] [Full Text] |
||||
|
Hypertension Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 1986 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |